Trial reportHuman vaccines & immunotherapeutics2023
Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10.
Trial report in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.Human vaccines & immunotherapeutics · 2025Pooled it
- Article
- Implementation Strategies to Enhance Confidence in a Whole Team Approach to Human Papillomavirus Vaccine Communication in Pediatric Care.Academic pediatrics · 2026Article
- Analysis of the characteristics of parents' reasons for refusing HPV vaccination for their daughters: a cross-sectional study.BMC public health · 2026Article
- Article
- Prevalence and inclusiveness of pay-for-performance incentives for HPV vaccination.The American journal of managed care · 2025Article
- Human papillomavirus vaccine administration opportunities at well visits in adolescents.BMC public health · 2025Article
- Article
- Article
- Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model.Frontiers in pediatrics · 2024Article
- Human papillomavirus vaccination at the first opportunity: An overview.Human vaccines & immunotherapeutics · 2023Review
- Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.Human vaccines & immunotherapeutics · 2023Article
- Optimizing Cancer Prevention in Adolescents by Improving HPV Vaccine Delivery.North Carolina medical journal · 2023Review
- How to make effective HPV vaccine recommendations starting at age 9.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proactive HPV vaccination at age 9 better prevents infection and improves vaccine series completion. Because national organizations recommend starting the vaccine at different ages, we sought to understand the impact of these recommendation frames. In 2022, we surveyed 2,527 US clinical staff (45% physicians) who provide HPV vaccine for children. We randomized respondents to one of three frames based on HPV vaccine recommendations of national organizations or a no-recommendation control, and assessed willingness to recommend HPV vaccine for children ages 9-10. Respondents also reported perceived benefits of HPV vaccination at ages 9 or 12. Recommending HPV vaccination "at ages 11-12" led to lower willingness to vaccinate at ages 9-10 than control (37% vs. 54%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.